中国医科大学学报2017，Vol.46Issue(2)：120-125,6.DOI:10.12007/j.issn.0258-4646.2017.02.006
c-FLIPL在白血病中的表达及临床意义
Expression of c-FLIPL in Leukemia and Its Clinical Significance
摘要
Abstract
Objective To investigate the expression of c-FLIPL in leukemia and explore its clinical significance. Methods The expression level of c-FLIPL mRNA in bone marrow mononuclear cells was determined by real-time polymerase chain reaction(PCR)in 103 leukemia patients with different types of leukemia,including 54 cases of acute lymphocytic leukemia(ALL)with 37 newly diagnosed,5 relapsed,and 12 complete remis-sion,38 cases of acute myeloid leukemia(AML)with 24 newly diagnosed,6 relapsed,and 8 complete remission,newly diagnosed 2 cases of acute undifferentiated leukemia(AUL),6 cases of chronic myelocytic leukemia(CML),and 3 cases of chronic myelomonocytic leukemia(CM-ML). The immunophenotype of patients were detected by flow cytometry. Results Expression level of c-FLIPL mRNA was higher in newly diag-nosed and relapsed leukemia patients. There was no significant difference between newly diagnosed and relapsed leukemia patients(P>0.05). Ex-pression level of c-FLIPL mRNA of AUL and CML was higher than that in other patients ,but there was no significant difference(P>0.05). Ex-pression level of c-FLIPL mRNA of all newly diagnosed and relapsed leukemia patients was significantly higher than that in control group and com-plete remission group(P<0.05). The expression level of c-FLIPL mRNA was correlated with risk stratification ,white blood cell(WBC),lactate dehydrogenase(LDH),hydroxybutyrate dehydrogenase(HBDH),CD45 and TEL-AML1,but was not associated with age,sex,fibrinogen and chromosome abnormality. Conclusion c-FLIPL mRNA is highly expressed in leukemia patients ,and is closely related with risk stratification , WBC,LDH,HBDH and prognosis.关键词
c-FLIPL/白血病/实时PCRKey words
c-FLIPL/leukemia/real-time polymerase chain reaction分类
医药卫生引用本文复制引用
迟昨非,何秋颖,杨威,傅煜,符爽,庄倩..c-FLIPL在白血病中的表达及临床意义[J].中国医科大学学报,2017,46(2):120-125,6.基金项目
沈阳市科技计划(F13-316-1-08) （F13-316-1-08）
